MindRank Pharma Showcases AI-Driven Drug Pipeline and Platforms at ChinaBio® Partnering Forum 2024

September 10-11, 2024The 16th ChinaBio^®Cooperation ForumSuccessfully held in Shanghai. As the largest and most effective international cooperation conference in China's life science field, the forum attracted more than 400 companies and over 800 decision-makers, executives, investors, and experts from the global life science industry to explore collaboration opportunities.

"MindRank" attended this forum as a representative enterprise in China's AI pharmaceuticals field.Founder and CEO Zhangming Niu gave a speech titled “Artificial Intelligence (AI)-Powered Precision Drug Discovery"Keynote Speech,Sharing the progress of the company's new drug pipeline under research. "MindRank" launches its self-developed GLP-1RA oral small molecule new drug for the first time.MDR-001 is proceeding smoothly with its Phase II clinical study, and multiple innovative anti-tumor drugs have entered the IND-Enabling stage.Relying on advanced AI algorithm underlying models, MindRank's self-developed AI pharmaceutical platform can precisely design and optimize molecular properties, aiming to efficiently develop candidate drugs with better efficacy and rapidly advance them to the clinical validation stage.

ChinaBio^®Exhibition Site

At the forum, the "MindRank" team showcased the company's latest AI pharmaceutical platform products, shared successful application cases with numerous global partners and pharmaceutical companies, and held in-depth discussions on product licensing and platform cooperation, actively expanding new partnerships.

Currently, "MindRank" is leveraging cutting-edge AI large model technology to continuously expand its proprietary AIDD capabilities from small molecule drugs to diversified modalities.An industrial-grade one-stop AI pharmaceutical platform, including PharmKG™, Molecule Dance™, and Molecule Pro™, as well as an innovative technology platform focused on large molecule and molecular glue drug discovery, has been established.

"MindRank's No.1 Virtual Employee, Xiao De"

Take You Back to ChinaBio^®Wonderful Moments ↓

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

MindRank's AI pharmaceutical solutions were rated by the authoritative European and American institution Deep Pharma Intelligence as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list.

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai